Digital education for cancer symptom management
Digital Intervention for Gastrointestinal (GI) Cancer Patients: A Case Study on Enhancing Symptom Self-Management During Treatment
This study tests a digital education program to help cancer patients undergoing chemotherapy better manage their symptoms and take an active role in their care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 110 (estimated) |
| Sex | All |
| Sponsor | Tel Aviv University Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Tel Aviv) |
| Trial ID | NCT06187610 on ClinicalTrials.gov |
What this trial studies
This study evaluates a digital education intervention designed to enhance self-management of symptoms in cancer patients undergoing chemotherapy. It focuses on the types of knowledge necessary for effective symptom management and active participation in healthcare. By leveraging telemedicine, the study aims to provide evidence-based instructional design to support patients in their treatment journey. The research specifically targets gastrointestinal cancer patients receiving chemotherapy, utilizing a structured educational approach.
Who should consider this trial
Good fit: Ideal candidates for this study are Hebrew-speaking patients diagnosed with gastrointestinal cancer who are currently undergoing specific chemotherapy treatments.
Not a fit: Patients with impaired cognitive capabilities or those who have discontinued treatment due to terminal disease progression may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could empower cancer patients to better manage their symptoms and improve their overall treatment experience.
How similar studies have performed: While there is limited research specifically on digital education for cancer symptom management, similar approaches in telemedicine have shown promise in enhancing patient engagement and outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Gastrointestinal (GI) cancer patients * Chemotherapy session within a specific round of treatment, with eligible treatments including FOLFOX, FOLFIRINOX, and FLOT. * Hebrew speakers. Exclusion Criteria: * Impaired or degraded cognitive capabilities that may hinder effective learning. * Individuals who discontinue their treatments due to terminal advancement of their disease or death.
Where this trial is running
Tel Aviv
- Ichilov Hospital — Tel Aviv, Israel (Recruiting)
Study contacts
- Study coordinator: Ilana Dubovi
- Email: tairvi@gmail.com
- Phone: +97254-7922358
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.